W William Cox, MD
Hematology & Oncology · Suite 1, AKNPI 1114912094
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,100 of the $3,397 with a category attached, or 61.8%. Pfizer accounts for 62.6% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $2,197, more than ten times the $138 reported in 2019.
Across 36 payments — averaging $94.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Inari Medical, Inc.$796
- Genentech USA, Inc.$114
- AstraZeneca$99
- E.r. Squibb & Sons, L.L.C.$48
- Celltrion USA Inc.$34
- plus $180 from 8 others
What the payments were for
- Consulting fees$2,10062%
- Food & beverage$1,28338%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $2,126 |
| Inari Medical, Inc. | 12 | $796 |
| Genentech USA, Inc. | 5 | $114 |
| AstraZeneca(2 entities) | 4 | $99 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Celltrion USA Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $28 |
| Foundation Medicine, Inc. | 1 | $27 |
| Amgen | 1 | $26 |
| AbbVie | 1 | $26 |
| Incyte Corporation | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
| Immunogen, Inc. | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 23 | $513,709 |
| RevlimidLenalidomide | 25 | $429,669 |
| Lenalidomide | 31 | $389,340 |
| CalquenceAcalabrutinib Maleate | 19 | $320,149 |
| ErleadaApalutamide | 20 | $301,830 |
| VenclextaVenetoclax | 19 | $282,208 |
| NubeqaDarolutamide | 15 | $195,370 |
| Abiraterone Acetate | 77 | $157,951 |
| XtandiEnzalutamide | 11 | $154,592 |
| Imatinib Mesylate | 11 | $2,589 |
| Hydroxyurea | 29 | $1,332 |
| Dexamethasone | 26 | $1,100 |
| Prochlorperazine Maleate | 48 | $910 |
| Pantoprazole Sodium | 50 | $749 |
| Acyclovir | 41 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $48 | $513,70923 claims |
| AstraZenecaCalquence | $99 | $320,14919 claims |
| Johnson & JohnsonErleada | $28 | $301,83020 claims |
| AbbVieVenclexta | $26 | $282,20819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other hematology & oncology in Suite 1
- Steven LiuAnchorage$35K
- David EilenderSoldotna$19K
- Max RabinowitzAnchorage$14K
- Mary KlixAnchorage$13K
- Mary StewartAnchorage$9K
- Kendal WebbAnchorage$8K
- Natalie WallaceAnchorage$8K
- Shannon SmileyAnchorage$6K
- Charles BuessAnchorage$5K
- Anusiyanthan MariampillaiAnchorage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.